Switch theme
Sign up to access all valuation multiples
Bioneer Corp engages in the manufacture and sale of biotechnological products in South Korea. It offers deoxyribonucleic acid (DNA) reagents, molecular diagnostic kits, DNA and ribonucleic acid (RNA) amplification products, human diagnostics kits, veterinary diagnostics kits, among others.
1992
n/a
LTM Revenue n/a
LTM EBITDA n/a
$278M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bioneer has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Bioneer achieved revenue of $200M and an EBITDA of -$1.9M.
Bioneer expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bioneer valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $179M | $200M | XXX | XXX | XXX |
| Gross Profit | $114M | $138M | XXX | XXX | XXX |
| Gross Margin | 63% | 69% | XXX | XXX | XXX |
| EBITDA | $7.0M | -$1.9M | XXX | XXX | XXX |
| EBITDA Margin | 4% | -1% | XXX | XXX | XXX |
| Net Profit | $8.2M | -$7.2M | XXX | XXX | XXX |
| Net Margin | 5% | -4% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Bioneer's stock price is KRW 16590 (or $11).
Bioneer has current market cap of KRW 428B (or $292M), and EV of KRW 408B (or $278M).
See Bioneer trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $278M | $292M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Bioneer has market cap of $292M and EV of $278M.
Bioneer's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Bioneer's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Bioneer and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $278M | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | -146.7x | XXX | XXX | XXX |
| P/E | -20.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -15.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBioneer's NTM/LTM revenue growth is n/a
Bioneer's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Bioneer's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Bioneer's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Bioneer and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -1% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -127% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 59% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 79% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bioneer acquired XXX companies to date.
Last acquisition by Bioneer was XXXXXXXX, XXXXX XXXXX XXXXXX . Bioneer acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Bioneer founded? | Bioneer was founded in 1992. |
| Where is Bioneer headquartered? | Bioneer is headquartered in South Korea. |
| Who is the CEO of Bioneer? | Bioneer's CEO is Mr. Han-Oh Park. |
| Is Bioneer publicy listed? | Yes, Bioneer is a public company listed on KRX. |
| What is the stock symbol of Bioneer? | Bioneer trades under 064550 ticker. |
| When did Bioneer go public? | Bioneer went public in 2005. |
| Who are competitors of Bioneer? | Similar companies to Bioneer include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Bioneer? | Bioneer's current market cap is $292M |
| What is the current revenue growth of Bioneer? | Bioneer revenue growth between 2023 and 2024 was 12%. |
| Is Bioneer profitable? | Yes, Bioneer is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
